Continuing Trastuzumab After Progression Shows Promise in HER2+ Gastric/GEJ Cancer
Adding anti-HER2 agent to ramucirumab, paclitaxel exceeds historical PFS with doublet
Source: medpagetoday.com
Sun Young Rha News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sun Young Rha. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sun Young Rha Today - Breaking & Trending Today
FDA Accepts sBLA for Pembrolizumab Plus Chemotherapy in Advanced Gastric/GEJ Adenocarcinoma
The FDA has accepted for review a supplemental biologics license application for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: onclive.com
Frontline Pembrolizumab Improves PFS, OS in HER2- Gastric/GEJ Cancers
Adding pembrolizumab to frontline chemotherapy improves outcomes in patients with HER2-, advanced gastric or GEJ cancers, a phase 3 trial suggests.
Source: oncologynurseadvisor.com
Frontline Pembrolizumab Improves PFS, OS in HER2- Gastric/GEJ Cancers
Adding pembrolizumab to frontline chemotherapy improves outcomes in patients with HER2-, advanced gastric or GEJ cancers, a phase 3 trial suggests.
Source: cancertherapyadvisor.com
Bold Therapeutics Extends South Korea Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic
/PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement...
Source: prnewswire.com